Therapeutic management of gliosarcoma in the temozolomide era

Mary F.rances McAleer, Paul D. Brown

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

Gliosarcoma (GS) is a malignant, uncommon variant of high-grade glioma comprised of infiltrative glial and atypical sarcomatous cells, identified in adult and pediatric populations. GS has been subcategorized into primary (de novo) and secondary tumors, with the latter typically arising in the setting of prior glioblastoma. Due to its rarity, the pathogenesis, epidemiology and optimal therapy of GS have been based on small retrospective cohort studies, with treatment presently utilizing regimens established for other high-grade gliomas, including combination of resection, radiotherapy and temozolomide-based chemotherapy. As more information is gathered about GS molecular profiles, novel treatment strategies may be developed to improve outcomes of GS patients. Here we summarize results of GS management with focus on the temozolomide era.

Original languageEnglish (US)
Pages (from-to)171-178
Number of pages8
JournalCNS oncology
Volume4
Issue number3
DOIs
StatePublished - 2015

Keywords

  • adult
  • gliosarcoma
  • high-grade glioma
  • management
  • pediatric
  • radiotherapy
  • surgery
  • temozolomide

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Therapeutic management of gliosarcoma in the temozolomide era'. Together they form a unique fingerprint.

Cite this